Lake, Jordan E.
Popov, Mikhail
Post, Wendy S.
Palella, Frank J.
Sacktor, Ned
Miller, Eric N.
Brown, Todd T.
Becker, James T.
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (U01 AI35042, U01 AI35039, U01 AI35040, U01 AI35041, UM1 AI35043, K23 AI110532, K24AI120834)
National Center for Advancing Translational Sciences (UL1 TR001079)
National Institute on Aging (AG 034852, P30 AG028748)
National Institute of Mental Health (MH 098745)
Article History
Received: 15 June 2016
Revised: 30 November 2016
Accepted: 6 December 2016
First Online: 15 December 2016
Compliance with ethical standards
:
: The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases, with additional co-funding from the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute of Mental Health. Targeted supplemental funding for specific projects was provided by the National Heart, Lung, and Blood Institute and the National Institute on Deafness and Communication Disorders. MACS data collection is also supported by UL1-TR001079 (Johns Hopkins University Institute for Clinical and Translational Research) from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the NIH, Johns Hopkins Institute for Clinical and Translational Research, or the National Center for Advancing Translational Sciences. Additional support for data analysis and manuscript preparation was provided by NIH grants AG034852 and MH098745 to JTB, K23AI110532 to JEL, K24 AI120834 to TTB, P30 AG028748, and P30 AI028697.
: JEL has served as a consultant to Gilead Sciences and GlaxoSmithKline. ENM is the author of the reaction time software used in this study (CalCAP) and has a financial interest in the software. TTB has served as a consultant to AbbVie, EMD-Serono, Merck, ViiV Healthcare and Gilead Sciences. MP, WSP, FJP, NS, and JTB declare that they have no conflict of interest.